Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
DEA temporarily places four new synthetic opioids in Schedule I, imposing immediate regulatory controls and potential criminal penalties for unauthorized handling.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 26, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All entities involved in the manufacturing, distribution, import/export, research, or handling of these specific substances, including API manufacturers, contract manufacturers, and research laboratories. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective immediately upon publication in the Federal Register (temporary scheduling is effective for up to two years).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Four new substances (5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine) are temporarily placed in Schedule I of the Controlled Substances Act, making them subject to the strictest regulatory controls.
Who it affects
All entities involved in the manufacturing, distribution, import/export, research, or handling of these specific substances, including API manufacturers, contract manufacturers, and research laboratories.
What you must do
Review current inventories and operations to determine if any of these substances are handled. If so, cease all activities unless authorized under a DEA registration or exemption, and consult legal counsel for compliance.
Deadline
Effective immediately upon publication in the Federal Register (temporary scheduling is effective for up to two years).
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Guidance: Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities
- FDA to require diversity plan for clinical trials - nature.com
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Second Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- FDA Issues Final Rule Clarifying Evidence of Off-Lab... - Dechert
- International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments